Effect of sparteine sulfate on uterine prostaglandin F in the rat

Abtahi, Farhad; Auletta, Frederick J.; Sadeghi, Dj.; Djahanguire, B.; Scommegna, Antonio

doi:10.1016/0090-6980(78)90227-7

Cited by 6 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sparteine is used in cardiac medicine due to its antiarrhythmic capacities (McCawley, 1955) and is frequently used in obstetrics. It induces the contraction of the uterus and hastens parturition by supporting the synthesis of prostaglandin F (Gray and Plentl, 1958;Abathi et al, 1978) . The other lupine alkaloids present in L. mutabilis have not been employed medically.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Quinolizidine alkaloids in seeds of Lupinus mutabilis

Hatzold¹,

Elmadfa²,

Gross³

et al. 1983

J. Agric. Food Chem.

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

“…The sites of cultivation were in the "Departamento Cuzco" in Peru (Urcos, 3125 m; Andenes, 3400 m; Ocongate, 3600 m; Paucartambo, 2910 m). The years of cultivation were 1978-1979and 1979. In 1979 no cultivation was carried out in Ocongate.…”

Section: Methodsmentioning

confidence: 99%

Quinolizidine alkaloids in seeds of Lupinus mutabilis

Hatzold¹,

Elmadfa²,

Gross³

et al. 1983

J. Agric. Food Chem.

View full text Add to dashboard Cite

“…One such mechanism is via the prostaglandin pathway, which was investigated in the rat by Abtahi et al. (). In in vivo experiments, they found that sparteine (10 mg/kg bw) increased the prostaglandin F concentration in plasma and uterine tissue of pregnant, but not of non‐pregnant rats.…”

Section: Assessmentmentioning

confidence: 99%

Scientific opinion on the risks for animal and human health related to the presence of quinolizidine alkaloids in feed and food, in particular in lupins and lupin‐derived products

Schrenk¹,

Bodin²,

Chipman³

et al. 2019

EFS2

View full text Add to dashboard Cite

The European Commission asked EFSA for a scientific opinion on the risks for animal and human health related to the presence of quinolizidine alkaloids (QAs) in feed and food. This risk assessment is limited to QAs occurring in Lupinus species/varieties relevant for animal and human consumption in Europe (i.e. Lupinus albus L., Lupinus angustifolius L., Lupinus luteus L. and Lupinus mutabilis Sweet). Information on the toxicity of QAs in animals and humans is limited. Following acute exposure to sparteine (reference compound), anticholinergic effects and changes in cardiac electric conductivity are considered to be critical for human hazard characterisation. The CONTAM Panel used a margin of exposure (MOE) approach identifying a lowest single oral effective dose of 0.16 mg sparteine/kg body weight as reference point to characterise the risk following acute exposure. No reference point could be identified to characterise the risk of chronic exposure. Because of similar modes of action for QAs, the CONTAM Panel used a group approach assuming dose additivity. For food, the highest mean concentration of Total QAs (TotQAs) (i.e. the 6 most abundant QAs) was found in lupin seed samples classified as 'Lupins (dry) and similar-'. Due to the limited data on occurrence and consumption, dietary exposure was calculated for some specific scenarios and no full human health risk characterisation was possible. The calculated margin of exposures (MOEs) may indicate a risk for some consumers. For example, when lupin seeds are consumed without a debittering step, or as debittered lupin seeds high in QA content and when 'lupin-based meat imitates' are consumed. For horses, companion and farm animals, other than salmonids, the available database on adverse effects was too limited to identify no-observed-adverse-effect levels and/or lowest-observed-adverse-effect levels and no risk characterisation was possible. For salmonids, the CONTAM Panel considers the risk for adverse effects to be low.This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.The EFSA Journal is a publication of the European Food Safety Authority, an agency of the European Union. Quinolizidine alkaloids in feed and food www.efsa.europa.eu/efsajournal 2 EFSA Journal 2019;17(11):5860 Quinolizidine alkaloids in feed and food www.efsa.europa.eu/efsajournal 3 EFSA Journal 2019;17(11):5860lupanine or 13a-OH-lupanine (each equivalent to 0.14 mg/kg bw for a person with a body weight of 70 kg). Human cases of poisoning with lupin seeds are infrequent and rarely lead to a fatal outcome. However, case reports of poisoning in children suggest that these are more susceptible to intoxication than adults, and doses of lupin alkaloids from 10 mg/kg bw onwards may be lethal. Intoxication have been associated with inadequate debittering of lupin seeds by consumers, while no case of poisoning has been...

show abstract

“…In particular, cell culture experiments revealed that sparteine may interact at high affinity with nicotinic (Haefely, 1974; Sakurai et al, 1982; Voitenko et al, 1991; Daly, 2005) and muscarinic acetylcholine receptor sites (Schmeller and Wink, 1988; Schmeller et al, 1994; Onodera and Shinoda, 1991). Moreover, sparteine was observed to affect prostaglandin F synthesis in rat uterine tissue (Abtahi et al, 1978). In a case of sparteine intoxication by ingestion of lupine seed extracts, classic anti‐cholinergic signs have been observed (Tsiodras et al, 1999).…”

Section: Introductionmentioning

confidence: 99%

Neuronal damage and changes in the expression of muscarinic acetylcholine receptor subtypes in the neonatal rat cerebral cortical upon exposure to sparteine, a quinolizidine alkaloid

Flores-Soto

Bañuelos-Pineda

Orozco‐Suárez³

et al. 2006

Intl J of Devlp Neuroscience

View full text Add to dashboard Cite

Sparteine is a quinolizidine alkaloid (QA) produced by Lupine species that has generated much interest due to its anti-hypertensive, anti-pyretic, and anti-inflammatory properties. In the nervous system, sparteine has been shown to display anti-cholinergic and depressive activity, although how sparteine exerts its toxic effects in the brain remains unclear. We have addressed this issue by administering subcutaneous injections of sparteine (25 mg/kg of body weight) to rats on postnatal days 1 and 3, and then examining the expression of the muscarinic acetylcholine receptor (mAChR) subunits m1-m4 in the brains of the neonatal rats 14-60 days later. Administration of sparteine to neonatal rats caused neuronal damage in the cerebral motor cortex accompanied by transient changes in the expression of m1-m4 mAChR subunits as revealed by both RT-PCR and Western blotting. This effect could be prevented by pre-treatment with atropine (10 mg/kg) 1 h prior to the injection of sparteine, suggesting that the cytotoxic activity of sparteine is mediated through mAChRs.

show abstract

Effect of sparteine sulfate on uterine prostaglandin F in the rat

Cited by 6 publications

References 16 publications

Quinolizidine alkaloids in seeds of Lupinus mutabilis

Quinolizidine alkaloids in seeds of Lupinus mutabilis

Scientific opinion on the risks for animal and human health related to the presence of quinolizidine alkaloids in feed and food, in particular in lupins and lupin‐derived products

Neuronal damage and changes in the expression of muscarinic acetylcholine receptor subtypes in the neonatal rat cerebral cortical upon exposure to sparteine, a quinolizidine alkaloid

Contact Info

Product

Resources

About